血管内皮生长因子评价伽玛刀治疗胰腺癌的疗效

目的 分析血管内皮生长因子(VEGF)水平与伽玛刀治疗胰腺癌疗效的关系,探讨其临床意义.方法 检测30例胰腺癌患者伽玛刀治疗前和治疗1个月后VEGF水平,分析其与疗效、患者生存期、生活质量的关系.结果 胰腺癌患者伽玛刀治疗前血清VEGF为(624.1±144.3)pg/ml,治疗1个月后为(279.3±83.4)pg/ml(P＜0.01).VEGF含量下降≥50%的19例中,CR+PR 18例,生活质量改善7例;VEGF下降＜50%的11例中,CR+PR 7例,生活质量改善1例,两组相差显著(P=0.012,P=0.028).随访满2年的24例患者中,VEGF下降≥50%的15例,1年生存率73.3%(11/15),显著高于VEGF下降＜50%者的22.2%(2/9,P＜0.033).结论 伽玛刀治疗后胰腺癌患者血清VEGF水平下降,其下降幅度可作为评价疗效的指标.

Vascular epidermis growth factor as a surrogate to evaluate the therapeutic efficacy of pancreatic cancer treated by gamma rays

Objective To analyze the relationship between the change of serum vascular epidermis growth factor(VEGF) level and curative effect of pancreatic cancer treated by gamma rays, and evaluate it clinical significance. Methods The serum VEGF level of thirty patients with pancreatic cancer treated by gamma rays were determined before and one month after treatment. The relationship between curative effect,survival, life quality and the serum VEGF level was analyzed. Results The serum VEGF level of 30 cases before treatment was (624.1 ± 144.3) pg/ml, whereas one month after treatment it was (279.3 ± 83.4) pg/ml(P ＜0.01 ). In the 19 patient whose serum VEGF level decreased by more than 50%, CR + PR was gained in 18 patients, improved quality of life in 7 patients, and in the 11 patient whose serum VEGF level decreased by less than 50%, CR + PR in 7 patients, improved quality of life in 1 patient( P = 0.012, P = 0. 028). In 24patients who completed 2 years follow-up, 11 of 15 patients whose serum VEGF level decreased by more than 50% survived more than 1 year, which was higher than that of the patients whose serum VEGF level decreased by less than 50%. Conclusions The serum VEGF level decreased significantly after gamma rays treatment and the extent of decrease could be used as a surrogate to evaluate the therapeutic efficacy.